P53-responsive genes and the potential for cancer diagnostics and therapeutics development

Biotechnology Annual Review

Volumn 7, Issue , 2001, Pages 131-164

  Xu, Hao ^a   El Gewely, M Raafat ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

14 3 3 ; 2 D gel electrophoresis; Apoptosis; Bax; Bcl 2; Cell cycle; Differential display; DNA microarrays chips; DNA repair; Functional genomics; G1 arrest; G2 arrest; p21WAF1; p53 domains; Proteomics; SAGE; Transactivation; Transrepression

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA ACTIN; ANGIOGENESIS INHIBITOR; CATHEPSIN D; CAVEOLIN; CYANOCOBALAMIN BINDING PROTEIN; CYCLIN G1; CYCLINE; CYTOCHROME C OXIDASE; DNA TOPOISOMERASE; EPHRIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; GLYPICAN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEME OXYGENASE; PROTEIN BAK; PROTEIN BAX; PROTEIN C FOS; PROTEIN P22; PROTEIN P53; PROTEIN P85; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; SOMATOMEDIN BINDING PROTEIN 3; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; CANCER DIAGNOSIS; CANCER GENETICS; CANCER THERAPY; CELL ADHESION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DISPLAY; DNA MICROARRAY; DNA REPAIR; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; FEEDBACK SYSTEM; FUNCTIONAL GENOMICS; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENETIC STABILITY; HUMAN; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR LOCALIZATION SIGNAL; OLIGOMERIZATION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SERIAL ANALYSIS OF GENE EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TWO DIMENSIONAL GEL ELECTROPHORESIS; BIOLOGICAL MODEL; BIOTECHNOLOGY; CHEMISTRY; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BIOTECHNOLOGY; DNA REPAIR; GENE EXPRESSION PROFILING; GENES, P53; GENOMICS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035228786     PISSN: 13872656     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1387-2656(01)07035-1     Document Type: Article

References (162)

1. Oren M, Rotter V. Introduction: p53-the first twenty years. Cell Mol Life Sci 1999;55:9-11.
2. Somasundaram K, El-Deiry WS. Tumor suppressor p53:regulation and function. Front Biosci 2000;5:d424-37.
3. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999;18:7621-36.
4. Bates S, Vousden KH. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 1999;55:28-37.
5. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-6.
6. Sionov RV, Haupt Y. The cellular response to p53:the decision between life and death. Oncogene 1999;18:6145-57.
7. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
8. Kunz C, Pebler S, Otte J, von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 1995;23:3710-7.
9. Murphy M, Hinman A, Levine AJ. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 1996;10:2971-80.
10. Nishimori H, Shiratsuchi T, Urano T, Kimura Y, Kiyono K, Tatsumi K, Yoshida S, Ono M, Kuwano M, Nakamura Y, Tokino T. A novel brain-specific p53-target gene, BI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 1997;15:2145-50.
11. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997;17:6330-8.
12. Ioachim EE, Athanassiadou SE, Kamina S, Carassavoglou K, Agnantis NJ. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices. Anticancer Res 1998;18:1665-70.
13. Utrera R, Collavin L, Lazarevic D, Delia D, Schneider C. A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression. EMBO J 1998;17:5015-25.
14. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999;274:10911-5.
15. Sun Y, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS. P53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem 1999;274:11535-40.
16. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 1999;18:5954-8.
17. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 1999;96:14517-22.
18. Loging WT, Reisman D. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. Oncogene 1999;18:7608-15.
19. Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, Altman RD, Howell DS, Cheung HS. Wild type and mutant p53 differentially regulate the gene expression of human colagenase-3 (hMMP-13). J Biol Chem 2000;275:11327-32.
20. Albrechtsen FJ, Dornreiter I, Wiesmuller L, Grosse F, Deppert W. The dual role model for p53 in maintaining genomic integrity. Cell Mol Life Sci 1999;55:12-27.
21. Jayaraman L, Prives C. Covalent and noncovalent modifiers of the p53 protein. Cell Mol Life Sci 1999;55:76-87.
22. Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene 1999;18:7637-43.
23. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999;18:7644-55.
24. Jimenez GS, Khan SH, Stommel JM, Wahl GM. P53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 1999;18:7656-65.
25. Meek DW. Mechanisms of switching on p53:a role for covalent modification? Oncogene 1999;18:7666-75.
26. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999;274:36031-4.
27. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000;10:94-9.
28. Caspari T. How to activate p53. Curr Biol 2000;10:R315-7.
29. Pfeifer GP, Holmquist GP. Mutagenesis in the p53 gene. Biochim Biophys Acta 1997;1333:M1-8.
30. Wallace-Brdeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999;54:64-75.
31. Gray JW, Collins C. Genome changes and gene expression in human solid tumors. Carcinogenesis 2000;21:443-52.
32. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998;292:435-45.
33. Woychik RP, Klebig ML, Justice MJ, Magnuso TR, Avrer ED. Functional genomics in the postgenome era. Mutat Res 1998;400:3-14.
34. Brent R. Functional genomics: learning to think about gene expression data. Curr Biol 1999;9:R338-41.
35. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
36. Maxwell SA. Two-dimensional gel analysis of p53-mediated changes in protein expression. Anticancer Res 1994;14:2549-56.
37. He C, Merrick BA, Patterson RM, Selkirk JK. Altered protein synthesis in p53 null and hemizygous transgenic mouse embryonic fibroblasts. Appl theor Electrophor 1995;5:15-24.
38. Merrick BA, Pence PM, He C, Patterson RM, Selkirk JK. Phosphor image analysis of human p53 protein isoforms. Biotechniques 1995;18:292-9.
39. Patterson RM, He C, Selkirk JK, Merrick BA. Human p53 expressed in baculovirus-infected Sf9 cells displays a two-dimensional isoform pattern identical to wild-type p53 from human cells. Arch Biochem Biophys 1996;330:71-9.
40. Maxwell SA, Roth JA, Mukhopadhyay T. Analysis of phosphorylated isoforms of the p53 tumor suppressor protein in human lung carcinoma cells undergoing apoptosis. Electrophoresis 1996;17:1772-5.
41. Pipkin JL, Hinson WG, James SJ, Lyn-Cook LE, Duffy PH, Feuers RJ, Shaddock JG, Aly KB, Hart RW, Casciano DA. P53 synthesis and phosphorylation in the aging diet-restricted rat following retinoic acid administration. Mech Ageing Dev 1997;97:15-34.
42. Madden SL, Galella EA, Zhu J, Bertelsen AH, Beaudry GA. SAGE transcript profiles for p53-dependent growth regulation. Oncogene 1997;15:1079-85.
43. Kobayashi T, Ruan S, Jabbur JR, Consoli U, Clodi K, Shiku H, Owen-Schaub LB, Andreeff M, Reed JC, Zhang W. Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ 1998;5:584-91.
44. Zhang R, Averboukh L, Zhu W, Zhang H, Jo H, Dempsey PJ, Coffey RJ, Pardee AB, Liang P. Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation. Mol Cell Biol 1998;18:6131-41.
45. Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 1999;91:143-51.
46. Reimer CL, Borras AM, Kurdistani SK, Garreau JR, Chung M, Aaronson SA, Lee SW. Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells. J Biol Chem 1999;274:11022-9.
47. Okamura S, Ng CC, Koyama K, Yakei Y, Arakawa H, Mouden M, Nakamura Y. Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system. Oncol Res 1999;11:281-5.
48. Roperch JP, Lethrone F, Prieur S, Piouffre L, Israeli D, Tuynder M, Neman M, Pasturaud P, Gendron MC, Dausset J, Oren M, Amson RB, Telerman A. SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: identification of common effectors with p53 and p21 (Waf1). Proc Natl Acad. Sci USA 1999;96:8070-3.
49. Lo PK, Chen JY, Lo WC, Chen BF, Hsin JP, Tang PP, Wang FF. Identification of a novel mouse p53 target gene DDA3. Oncogene 1999;18:7765-74.
50. Fernandez-Salas E, Sagar M, Cheng C, Yuspa SH, Weinberg WC. P53 and tumor necrosis factor alpha regulate the expression of a mitochondrial chloride channel protein. J Biol Chem 1999;274:36488-97.
51. Yam JW, Zheng JY, Hsiao WL. Identification and characterization of genes whose expressions are altered in rat 6 fibroblasts transformed by mutant p53(val135). Biochem Biophys Res Commun 1999;266:472-80.
52. Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, Shields PG, Modali R, Turner BC. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 2000;60:1062-9.
53. Relaix F, Wei X, Li W, Pan J, Lin Y, Bowtell DD, Sassoon DA, Wu X. Pw1/Peg3 is a potential cell death mediator and cooperates with Siahla in p53-mediated apoptosis. Proc Natl Acad Sci USA 2000;97:2105-10.
54. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fakuda S, Matsui K, Takei Y, Nekamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000;404:42-9.
55. Kannan K, Amariglio N, Rechavi G, Givol D. Profile of gene expression regulated by induced p53:connection to the TGF-β family. FEBS Lett 2000;470:77-82.
56. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
57. Favis R, Barany F. Mutation detection in k-ras, BRCA1, BRCA2, and p53 using PCR/LDR and a universal DNA microarray. Ann NY Acad Sci 2000;906:39-43.
58. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000;14:981-93.
59. Okamoto T, Suzuki T, Yamamoto N. Microarray fabrication with covalent attachment of DNA using bubble jet technology. Nat Biotechnol 2000;18:438-41.
60. Wen WH, Bernstein L, Lescallett J, Beazer-Barclay Y, Sullivan-Halley J, White M, Press MF. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 2000;60:2716-22.
61. Russo IH, Russo J. Hormonal approach to breast cancer prevention. J Cell Biochem Suppl 2000;34:1-6.
62. El-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998;8:345-57.
63. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 aminoterminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994;8:1235-46.
64. Zhu J, Zhou W, Jiang J, Chen X. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem 1998;273:13030-6.
65. Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L, Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J 1998;17:4668-79.
66. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992;1:45-9.
67. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
68. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995;267:1498-502.
69. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborn AM. Interhelical angles in the solution structure of the oligomerization domain of p53 correction. Science 1995;267:1515-6.
70. Hupp TR, Lane DP. Allosteric activation of latent p53 tetramers. Curr Biol 1994;4:865-75.
71. Hupp TR, Lane DP. Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J Biol Chem; 270:18165-74.
72. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998;12:2831-41.
73. Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 1998;18:5690-8.
74. Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y, Dejean A. c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem 2000;275:13321-9.
75. David-Pfeuty T, Chakrani F, Ory K, Nouvian-Dooghe Y. Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells. Cell Growth Differ 1996;7:1211-25.
76. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, Jaenisch R, Wahl GM. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 1998;8:145-55.
77. Pritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18.
78. Komarova EA, Zelnick CR, Chin D, Zeremski M, Gleiberman AS, Bacus SS, Gudkov AV. Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus. Cancer Res 1997;57:5217-20.
79. Liang SH, Hong D, Clarke MF. Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein. J Biol Chem 1998;273:19817-21.
80. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999;18:1660-72.
81. Alaiya AA, Franzen B, Auer G, Linder S. Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification. Electrophoresis 2000;21:1210-7.
82. Corthals GL, Wasinger VC, Hochstrasser DF, Sanchez JC. The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 2000;21:1104-15.
83. Xiang CC, Cheng Y. cDNA microarray technology and its applications. Biotechnology Advances 2000;18:35-46.
84. Dutt MJ, Lee KH. Proteomic analysis. Curr Opin Biotechnol 2000 Apr; 11(2):176-9.
85. Jurecic R, Belmont JW. Long-distance DD-PCR and cDNA microarrays. Curr Opin Microbiol 2000;3:316-21.
86. Lennon GG. High-throughput gene expression analysis for drug discovery. Drug Discov Today 2000;5:59-66.
87. Leveillard T, Andera L, Bissonnette N, Schaeffer L, Bracco L, Egly JM, Wasylyk B. Functional interactions between p53 and the TFIIH complex are affected by tumor-associated mutations. EMBO J 1996;15:1615-24.
88. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JH, Harris CC. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996;10:1219-32.
89. Schneider E, Montenarh M, Wagner P. Regulation of CAK kinase activity by p53. Oncogene 1998;17:2733-41.
90. Thornborrow EC, Manfredi JJ. One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. J Biol Chem 1999;274:33747-56.
91. Uesugi M, Verdine GL. The alpha-helical FXXPhiPhi motif in p53:TAF interaction and discrimination by MDM2. Proc Natl Acad Sci U S A 1999;96:14801-6.
92. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999;13:2490-501.
93. Moberg KH, Tyndall WA, Hall DJ. Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line. J Cell Biochem 1992;49:208-15.
94. Margulies L, Sehgal PB. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. J Biol Chem 1993;268:15096-100.
95. Ueba T, Noska T, Takahashi JA, Shibata F, Florkiewicz RZ, Vogelstein B, Oda Y, Kikuchi H, Hatanaka M. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Pro. Natl Acad Sci USA 1994;91:9009-13.
96. Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB. p53 activates expression of HIC-1, a new candidate tumor suppressor gene on 17pl3.3. Nat Med 1995;1:570-7.
97. Shin TH, Paterson AJ, Kudlow JE. P53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53. Mol Cell Biol 1995;15:4694-701.
98. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646-9.
99. Morris GF, Bischoff JR, Mathews MB. Transcriptional activation of the human proliferating cell nuclear antigen promoter by p53. Proc Natl Acad Sci USA 1996;93:895-9.
100. Takada S, Kaneniwa N, Tsuchida N, Koike K. Hepatitis B virus X gene expression is activated by X protein but repressed by p53 tumor suppressor gene product in the transient expression system. Virology 1996;216:80-9.
101. Harris LC, Remack JS, Houghton PJ, Brent TP. Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res 1996;56:2029-32.
102. Iotsova V, Stehelin D. Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein. Cell Growth Differ 1996;7:629-634.
103. Pesch J, Brehm U, Staib C, Grummt F. Repression of interleukin-2 and interleukin-4 promoters by tumor suppressor protein p53. J Interferon Cytokine Res 1996;16:595-600.
104. Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S. Transcriptional activation of the human epidermal growth factor receptor pro-moter by human p53. Mol Cell Biol 1996;16:6009-19.
105. Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, Vikhanskaya F. P53 regulates the minimal promoter of the human topoisomerase II alpha gene. Nucleic Acids Res 1996;24:4464-70.
106. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O'lomor PM, Appella E. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997;94:6048-53.
107. Israeli D, Tessler E, Haupt Y, Elkeles A, Wilder S, Amson R, Telerman A, Oren M. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J 1997;16:4384-92.
108. Neuberg M, Buckbinder L, Seizinger B, Kley N. The p53/IGF-1 receptor axis in the regulation of programmed cell death. Endocrine 1997;7:107-9.
109. Kato MV, Sato H, Nagayoshi M, Ikawa Y. Upregulation of the elongation factor-1α gene by p53 in association with death of an erythroleukemic cell line. Blood 1997;90:1373-78.
110. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389:300-5.
111. Knippschild U, Milne DM, Campbell LE, DeMaggio AJ, Christenson E, Hoekstra M, Meek DW. P53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs. Oncogene 1997;15:1727-36.
112. Wu GS, Burns TF, McDonald ER, III Jiang W, Meng R, Krantz ID, Kao G, Gan D-D, Zhou J-Y, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, El-Deiry WS. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet 1997;17:141-3.
113. Varmeh-Ziaie S, Okan I, Wang Y, Magnusson KP, Warthoe P, Strauss M, Wiman KG. Wig-1, a new p53-induced gene encoding a zinc finger protein. Oncogene 1997;15:2699-704.
114. Kagawa K, Inoue T, Tokino T, Nakamura Y, Akiyama T. Overexpression of GML promotes radiation induced cell cycle arrest and apoptosis. Biochem Biophys Res Commun 1997;241:481-5.
115. Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, Gamblin SJ, Smerdon SJ, Cantley LC. The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 1997;91:961-71.
116. Liu Y, Bohn SA, Sherley JL. Inosine-5́-monophosphate dehydrogenase is a rate-determining factor for p53-dependent growth regulation. Mol Biol Cell 1998;9:15-28.
117. Zhang L, Zhan Q, Zhan S, Kashanchi F, Fornace AJ, Seth P, Helman LJ. P53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. DNA Cell Biol 1998;17:125-31.
118. Yin Y, Terauchi Y, Solomon GG, Aizawa S, Rangarajan PN, Yazaki Y, Kadowaki T, Barrett JC. Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature 1998;391:707-10.
119. Comer KA, Dennis PA, Armstrong L, Catino JJ, Kastan MB, Kumar CC. Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein. Oncogene 1998;16:1299-308.
120. Woo GS, Saftig P, Peters C, El-Deiry WS. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 1998;16:2177-83.
121. Gopalkrishnan RV, Lam EWF, Kedinger C. The p53 tumor suppressor inhibits transcription of the TATA-less mouse DPI promoter. J Biol Chem 1998;273:10972-8.
122. Schafer H, Trauzold A, Sebens T, Deppert W, Folsch UR, Schmidt WE. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene. Oncogene 1998;16:2479-87.
123. Myung K, Braastad C, He DM, Hendrickson EA. KARP-1 is induced by DNA damage in a p53- and ataxia telangiectasia mutated-dependent fashion. Proc Natl Acad Sci USA 1998;95:7664-9.
124. Roperch JP, Alvaro V, Prieur S, Tuynder M, Nemani M, Lethrosne F, Piouffre L, Gendron MC, Israeli D, Dausset J, Oren M, Amson R, Telerman A. Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Mat Med 1998. 4:835-8.
125. Resnick-Silverman L, St Clair S, Maurer M, Zhao K, Manfredi JJ. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev 1998;12:2102-7.
126. Leach SD, Scatena CD, Keefer CJ, Goodman HA, Song SY, Yang L, Pietenpol JA. Negative regulation of Weel expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res 1998;58:3231-6.
127. Takei Y, Ishikawa S, Tokino T, Muto T, Nakamura Y. Isolation of a novel TP53 target gene from a colon cancer cell line carrying a highly regulated wild-type TP53 expression system. Genes Chromosomes Cancer 1998;23:1-9.
128. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH. p14ARF links the tumour suppressors RB andp53. Nature 1998;395:124-5.
129. Mashimo T, Watabe M, Hirota S, Hosobe S, Miura K, Tegtmeyer PJ, Rinker-Shaeffer CW, Watabe K. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc. Natl Acad Sci USA 1998;95:11307-11.
130. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
131. Wang Q, Beck, WT. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 1998;58:5762-9.
132. Sun Y, Wicha M Leopold WR. Regulation of metastasis-related gene expression by p53:a potential clinical implication. Mol Carcinog 1999;24:25-8.
133. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999;18:22-7.
134. Velasco-Miguel S, Buckbinder L, Jean P, Gelbert L, Talbott R, Laidlaw J, Seizinger B, Kley N. PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene 1999;18:127-37.
135. Budde A, Grummt I. p53 represses ribosomal gene transcription. Oncogene 1999;18:1119-24.
136. Lee KC, Crowe AJ, Barton MC. p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell Biol 1999;19:1279-88.
137. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Ailou T. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology 1999;57:131-7.
138. Seol D-W, Chen Q, Smith ML, Zarnegar R. Regulation of the c-met proto-oncogene promoter by p53. J Biol Chem 1999;274:3565-72.
139. Elkeles A, Juven-Gershon T, Israeli D, Wilder S, Zalcenstein A, Oren M. The c-fos protooncogene is a target for transactivation by the p53 tumor suppressor. Mol Cell Biol 1999;19:2594-600.
140. Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, Kane LS, Gow AJ, Stamler JS. Fas-induced caspase denitrosylation. Science 1999;284:651-4.
141. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999;399:483-7.
142. Gobert C, Skladanowski A, Larsen AK. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. Proc Natl Acad Sci USA 1999;96:10355-60.
143. Depraetere V, Golstein P. WW domain-containing FBP-30 is regulated by p53. Cell Death Differ 1999;6:883-9.
144. Zaika A, Marchenko N, Moll UM. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J Biol Chem 1999;274:27474-80.
145. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616-20.
146. Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schonthal AH, Katula KS, Stark GR. Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell 1999;10:3607-22.
147. Sheikh MS, Hollander MC, Fornance AJ Jr. Role of Gadd45 in apoptosis. Biochem Pharmacol 2000;59:43-5.
148. Tan M, Wang Y, Guan K, Sun Y. PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway. Proc Natl Acad Sci USA 2000;97:109-14.
149. Nylander K, Bourdon JC, Bray SE, Gibbs NK, Kay R, Hart I, Hall PA. Transcriptional activation of tyrosinase and TRP-1 by p53 links UV irradiation to the protective tanning response. J Pathol 2000;190:39-46.
150. Ferrero JM, Etienne MC, Formento JL, Francoual M, Rostagno P, Peyrottes I, Ettore F, Teissier E, Leblanc-Talent P, Namer M, Milano G. Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients. Br J Cancer 2000;82:171-7.
151. Guardavaccaro D, Corrente G, Covone F, Micheli L, D'Agnano I, Starace G, Caruso M, Tirone F. Arrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin Dl transcription. Mol Cell Biol 2000;20:1797-815.
152. Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, Srivastava S. p53 regulates the expression of the tumor suppressor gene Maspin. J Biol Chem 2000;275:6051-4.
153. Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, Jacks T. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev 2000;14:704-18.
154. Wang J, Shou J, Chen X. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by P53. Oncogene 2000;19:1843-8.
155. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H, Inoue M. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 2000;6:1239-47.
156. Kaluzova M, Pastorekova S, Pastorek J, Kaluz S. p53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in Ma Tu cells. Biochim Biophys Acad 2000;1491:20-6.
157. Janssens V, Van Hoof C, De Baere I, Merlevede W, Goris J. The phosphotyrosyl phosphatase activator gene is a novel p53 target gene. J Biol Chem 2000; In press.
158. Saifudeen Z, Du H, Dipp S, El-Dahr SS. The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation. J Biol Chem 2000;275:15557-62.
159. Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH, Biggs JR, Kraft AS, Yang VW. The gut-enriched kruppel-like factor (Kruppel-like factor n) mediates the transactivating effect of p53 on the p21WAF1/Cipl promoter. J Biol Chem 2000;275:18391-8.
160. She QB, Chen N, Dong Z. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem 2000; In press.
161. Webster GA, Perkins ND. Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 1999;19:3485-95.
162. Gray JW, Collins C. Genome changes and gene expression in human solid tumors. Carcinogenesis 2000;21:443-52.